vs
渤健（BIIB）与自由媒体集团（FWONA）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是自由媒体集团的1.4倍（$2.3B vs $1.6B），自由媒体集团净利率更高（20.7% vs -2.1%，领先22.8%），自由媒体集团同比增速更快（150.7% vs -7.1%），渤健自由现金流更多（$468.0M vs $62.0M），过去两年渤健的营收复合增速更高（-0.2% vs -23.5%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
自由媒体集团是1991年由约翰·C·马龙创立的美国大型传媒企业，旗下设有两大对应独立追踪股票的业务板块，持有一级方程式集团和Live Nation Entertainment的股权，截至2025年拥有F1、世界摩托车锦标赛、世界超级摩托车锦标赛三项全球顶级赛车运动IP及运营业务。
BIIB vs FWONA — 直观对比
营收规模更大
BIIB
是对方的1.4倍
$1.6B
营收增速更快
FWONA
高出157.9%
-7.1%
净利率更高
FWONA
高出22.8%
-2.1%
自由现金流更多
BIIB
多$406.0M
$62.0M
两年增速更快
BIIB
近两年复合增速
-23.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $1.6B |
| 净利润 | $-48.9M | $333.0M |
| 毛利率 | 78.3% | — |
| 营业利润率 | -2.5% | 14.0% |
| 净利率 | -2.1% | 20.7% |
| 营收同比 | -7.1% | 150.7% |
| 净利润同比 | -118.3% | 193.8% |
| 每股收益（稀释后） | $-0.35 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBFWONA
| Q4 25 | $2.3B | $1.6B | ||
| Q3 25 | $2.5B | $1.1B | ||
| Q2 25 | $2.6B | $1.3B | ||
| Q1 25 | $2.4B | $447.0M | ||
| Q4 24 | $2.5B | $-3.2B | ||
| Q3 24 | $2.5B | $911.0M | ||
| Q2 24 | $2.5B | $3.2B | ||
| Q1 24 | $2.3B | $2.7B |
净利润BIIBFWONA
| Q4 25 | $-48.9M | $333.0M | ||
| Q3 25 | $466.5M | $13.0M | ||
| Q2 25 | $634.8M | $204.0M | ||
| Q1 25 | $240.5M | $5.0M | ||
| Q4 24 | $266.7M | $-355.0M | ||
| Q3 24 | $388.5M | $-2.4B | ||
| Q2 24 | $583.6M | $457.0M | ||
| Q1 24 | $393.4M | $203.0M |
毛利率BIIBFWONA
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
营业利润率BIIBFWONA
| Q4 25 | -2.5% | 14.0% | ||
| Q3 25 | 22.0% | 13.7% | ||
| Q2 25 | 28.1% | 20.4% | ||
| Q1 25 | 12.8% | -15.9% | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 18.3% | 11.7% | ||
| Q2 24 | 28.3% | 16.7% | ||
| Q1 24 | 20.3% | 18.3% |
净利率BIIBFWONA
| Q4 25 | -2.1% | 20.7% | ||
| Q3 25 | 18.4% | 1.2% | ||
| Q2 25 | 24.0% | 15.2% | ||
| Q1 25 | 9.9% | 1.1% | ||
| Q4 24 | 10.9% | 11.2% | ||
| Q3 24 | 15.8% | -259.9% | ||
| Q2 24 | 23.7% | 14.4% | ||
| Q1 24 | 17.2% | 7.4% |
每股收益（稀释后）BIIBFWONA
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $3.17 | — | ||
| Q2 25 | $4.33 | — | ||
| Q1 25 | $1.64 | — | ||
| Q4 24 | $1.82 | — | ||
| Q3 24 | $2.66 | — | ||
| Q2 24 | $4.00 | — | ||
| Q1 24 | $2.70 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.1B |
| 总债务越低越好 | $6.3B | $5.1B |
| 股东权益账面价值 | $18.3B | $7.8B |
| 总资产 | $29.4B | $15.4B |
| 负债/权益比越低杠杆越低 | 0.34× | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资BIIBFWONA
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | — | $3.4B | ||
| Q1 25 | — | $3.1B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $3.1B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $1.7B |
总债务BIIBFWONA
| Q4 25 | $6.3B | $5.1B | ||
| Q3 25 | $6.3B | $7.0B | ||
| Q2 25 | $6.3B | $4.8B | ||
| Q1 25 | $4.5B | $4.6B | ||
| Q4 24 | $6.3B | $4.5B | ||
| Q3 24 | $4.5B | $4.4B | ||
| Q2 24 | $6.3B | $15.0B | ||
| Q1 24 | $6.3B | $15.4B |
股东权益BIIBFWONA
| Q4 25 | $18.3B | $7.8B | ||
| Q3 25 | $18.2B | $7.4B | ||
| Q2 25 | $17.6B | $7.3B | ||
| Q1 25 | $17.0B | $7.0B | ||
| Q4 24 | $16.7B | $7.0B | ||
| Q3 24 | $16.4B | $7.4B | ||
| Q2 24 | $15.9B | $17.1B | ||
| Q1 24 | $15.2B | $16.6B |
总资产BIIBFWONA
| Q4 25 | $29.4B | $15.4B | ||
| Q3 25 | $29.2B | $17.8B | ||
| Q2 25 | $28.3B | $13.8B | ||
| Q1 25 | $28.0B | $13.3B | ||
| Q4 24 | $28.0B | $12.9B | ||
| Q3 24 | $28.3B | $13.2B | ||
| Q2 24 | $26.8B | $42.6B | ||
| Q1 24 | $26.6B | $42.4B |
负债/权益比BIIBFWONA
| Q4 25 | 0.34× | 0.66× | ||
| Q3 25 | 0.35× | 0.95× | ||
| Q2 25 | 0.36× | 0.65× | ||
| Q1 25 | 0.27× | 0.65× | ||
| Q4 24 | 0.38× | 0.65× | ||
| Q3 24 | 0.28× | 0.59× | ||
| Q2 24 | 0.40× | 0.88× | ||
| Q1 24 | 0.41× | 0.93× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $123.0M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $62.0M |
| 自由现金流率自由现金流/营收 | 20.5% | 3.9% |
| 资本支出强度资本支出/营收 | 1.9% | 3.8% |
| 现金转化率经营现金流/净利润 | — | 0.37× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $789.0M |
8季度趋势，按日历期对齐
经营现金流BIIBFWONA
| Q4 25 | $511.9M | $123.0M | ||
| Q3 25 | $1.3B | $173.0M | ||
| Q2 25 | $160.9M | $231.0M | ||
| Q1 25 | $259.3M | $381.0M | ||
| Q4 24 | $760.9M | $-23.0M | ||
| Q3 24 | $935.6M | $182.0M | ||
| Q2 24 | $625.8M | $752.0M | ||
| Q1 24 | $553.2M | $395.0M |
自由现金流BIIBFWONA
| Q4 25 | $468.0M | $62.0M | ||
| Q3 25 | $1.2B | $170.0M | ||
| Q2 25 | $134.3M | $209.0M | ||
| Q1 25 | $222.2M | $348.0M | ||
| Q4 24 | $721.6M | $-46.0M | ||
| Q3 24 | $900.6M | $-153.0M | ||
| Q2 24 | $592.3M | $566.0M | ||
| Q1 24 | $507.3M | $194.0M |
自由现金流率BIIBFWONA
| Q4 25 | 20.5% | 3.9% | ||
| Q3 25 | 48.4% | 15.7% | ||
| Q2 25 | 5.1% | 15.6% | ||
| Q1 25 | 9.1% | 77.9% | ||
| Q4 24 | 29.4% | 1.4% | ||
| Q3 24 | 36.5% | -16.8% | ||
| Q2 24 | 24.0% | 17.9% | ||
| Q1 24 | 22.1% | 7.1% |
资本支出强度BIIBFWONA
| Q4 25 | 1.9% | 3.8% | ||
| Q3 25 | 1.8% | 0.3% | ||
| Q2 25 | 1.0% | 1.6% | ||
| Q1 25 | 1.5% | 7.4% | ||
| Q4 24 | 1.6% | -0.7% | ||
| Q3 24 | 1.4% | 36.8% | ||
| Q2 24 | 1.4% | 5.9% | ||
| Q1 24 | 2.0% | 7.3% |
现金转化率BIIBFWONA
| Q4 25 | — | 0.37× | ||
| Q3 25 | 2.73× | 13.31× | ||
| Q2 25 | 0.25× | 1.13× | ||
| Q1 25 | 1.08× | 76.20× | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | — | ||
| Q2 24 | 1.07× | 1.65× | ||
| Q1 24 | 1.41× | 1.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
FWONA
| Formula One | $1.4B | 87% |
| Product Service Or Other | $131.0M | 8% |
| Other | $77.0M | 5% |
